Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence
ABSTRACTMycobacterium abscessus pulmonary disease is increasing in prevalence globally, particularly for individuals with cystic fibrosis. These infections are challenging to treat due to a high rate of resistance. Amikacin is critical to treatment, but the development of toxicity, amikacin resistan...
Main Authors: | Joy E. Gibson, Nishant Nandanwar, Michael N. Neely |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2024-02-01
|
Series: | Microbiology Spectrum |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/spectrum.03222-23 |
Similar Items
-
Rapid Detection of Clarithromycin and Amikacin Resistance in Mycobacterium abscessus Complex by High-Resolution Melting Curve Analysis
by: Haoran Li, et al.
Published: (2022-06-01) -
Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database
by: Elsa Logre, et al.
Published: (2020-06-01) -
Treatment Outcome in Patients with <i>Mycobacterium abscessus</i> Complex Lung Disease: The Impact of Tigecycline and Amikacin
by: Jeng-How Yang, et al.
Published: (2022-04-01) -
The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
by: Khan O, et al.
Published: (2020-06-01) -
Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model
by: Etienne Vignaud, et al.
Published: (2025-01-01)